Description
Articles de périodiques scientifiques
Général
- Cystic Fibrosis Related Diabetes: Pathophysiology, Spectrum of Glycemic Abnormalities, and Evolving Approaches to Screeningon 11 mai 2026
Endocr Pract. 2026 Apr 29:S1530-891X(26)00963-8. doi: 10.1016/j.eprac.2026.04.016. Online ahead of print.ABSTRACTCystic Fibrosis Related Diabetes (CFRD) is a well-recognized and increasingly […]
- Continuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic controlon 11 mai 2026
Diabetes Res Clin Pract. 2026 Apr 20:113274. doi: 10.1016/j.diabres.2026.113274. Online ahead of print.ABSTRACTBACKGROUND/AIMS: Data for the use of continuous glucose monitoring (CGM) in cystic […]
- Association of CFRD development among females with CF who use hormonal contraceptionon 11 mai 2026
J Cyst Fibros. 2026 Apr 19:S1569-1993(26)00097-4. doi: 10.1016/j.jcf.2026.04.004. Online ahead of print.ABSTRACTBACKGROUND: Research suggests the effects of combined (containing both estrogen and […]
- Pulmonary infections in cystic fibrosis: A bibliometric mapping of global research themes (1950-2025)on 11 mai 2026
Respir Med. 2026 Apr 15:108823. doi: 10.1016/j.rmed.2026.108823. Online ahead of print.ABSTRACTBACKGROUND: Pulmonary infections remain the main cause of morbidity and mortality in cystic fibrosis […]
- An update on cystic fibrosis Hepato-biliary involvementon 11 mai 2026
J Cyst Fibros. 2026 Apr 9:S1569-1993(26)00090-1. doi: 10.1016/j.jcf.2026.03.022. Online ahead of print.ABSTRACTLiver involvement among people with cystic fibrosis (PwCF) has long been recognized as […]
- Oral health status in adult and paediatric patients with cystic fibrosis (CF): A systematic review and meta-analysison 11 mai 2026
Paediatr Respir Rev. 2026 Apr 14:S1526-0542(26)00027-8. doi: 10.1016/j.prrv.2026.04.003. Online ahead of print.ABSTRACTThe aim of this study was to evaluate oral health in paediatric and adult […]
- Kidney Failure in Persons With Cystic Fibrosison 11 mai 2026
Kidney Med. 2026 Jan 13;8(5):101263. doi: 10.1016/j.xkme.2026.101263. eCollection 2026 May.ABSTRACTRATIONALE & OBJECTIVES: Chronic kidney disease (CKD) occurs with increased frequency in people […]
Diagnostic et évaluation
- Bayesian Inferential Analysis of Genetic Risks Based on Family Historyon 11 mai 2026
Acta Biotheor. 2026 May 4;74(3):16. doi: 10.1007/s10441-026-09525-8.ABSTRACTClassical statistical analysis is a frequently employed methodology in numerous domains of genetic research. In recent […]
- Don't Forget Your Basics: A Late Diagnosis of Cystic Fibrosis in a Child.on 11 mai 2026
Journal of Pediatric Healthcare; 05/01/2026Delayed diagnosis of Cystic Fibrosis (CF) can occur. We present a 5-year African American boy with respiratory issues, fevers, rectal prolapse, oily stools, […]
- A Stepwise Multimodality Imaging Approach to Out-of-Hospital Cardiac Arrest in Cystic Fibrosison 11 mai 2026
Am J Cardiol. 2026 Apr 16:S0002-9149(26)00255-9. doi: 10.1016/j.amjcard.2026.04.029. Online ahead of print.ABSTRACTOut-of-hospital cardiac arrest (OHCA) without ST-segment elevation represents a […]
Interventions et traitements
- Considerations for early life genetic therapies in cystic fibrosison 11 mai 2026
Am J Physiol Lung Cell Mol Physiol. 2026 Apr 29. doi: 10.1152/ajplung.00022.2026. Online ahead of print.ABSTRACTCystic fibrosis (CF) is caused by mutations in the gene encoding for the CF […]
- Comparative and subtractive genomics reveals novel therapeutic targets in cystic fibrosis-associated multidrug-resistant Pandoraea sputorumon 11 mai 2026
Diagn Microbiol Infect Dis. 2026 Apr 10;115(4):117412. doi: 10.1016/j.diagmicrobio.2026.117412. Online ahead of print.ABSTRACTDespite increasing clinical reports of its emergence and multidrug […]
- Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patientson 11 mai 2026
J Cyst Fibros. 2026 Apr 14:S1569-1993(26)00096-2. doi: 10.1016/j.jcf.2026.04.003. Online ahead of print.ABSTRACTChronic rhinosinusitis with nasal polyps (CRSwNP) manifests as either a solitary upper […]
- Impact of two years of treatment with Elexacaftor/Tezacaftor/Ivacaftor on longitudinal changes in structural lung disease in people with Cystic Fibrosis - Results from the RECOVER trialon 11 mai 2026
Ann Am Thorac Soc. 2026 Feb 2:aaoag021. doi: 10.1093/annalsats/aaoag021. Online ahead of print.ABSTRACTRATIONALE: Progressive structural lung disease (SLD) is a key hallmark of cystic fibrosis. The […]
- Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosison 11 mai 2026
Adv Ther. 2026 Apr 16. doi: 10.1007/s12325-026-03599-z. Online ahead of print.ABSTRACTCystic fibrosis (CF) is a monogenic disorder leading to pulmonary disease, pancreatic insufficiency and cystic […]
- Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort Studyon 11 mai 2026
Respir Med. 2026 Apr 20:108827. doi: 10.1016/j.rmed.2026.108827. Online ahead of print.ABSTRACTBACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has demonstrated significant improvements in lung […]
- Progress towards regenerative therapies for the cystic fibrosis lung and pancreas: insights from stem cells and organoidson 11 mai 2026
J Cyst Fibros. 2026 May 8:S1569-1993(26)00103-7. doi: 10.1016/j.jcf.2026.04.010. Online ahead of print.ABSTRACTCystic fibrosis (CF), caused by mutations in the CFTR gene, is characterised by […]
Transplantation
- Lung transplant in people with cystic fibrosis and nontuberculous mycobacteria infectionon 11 mai 2026
Cochrane Database Syst Rev. 2026 Apr 21;4:CD016200. doi: 10.1002/14651858.CD016200.ABSTRACTRATIONALE: Cystic fibrosis (CF) is an inherited multi-organ disorder. People with CF (pwCF) experience […]
- A Deep Dive into Endocrine and Reproductive Health in Patients with Cystic Fibrosis: Before and Beyond Solid Organ Transplantationson 11 mai 2026
Endocr Pract. 2026 Apr 20:S1530-891X(26)00953-5. doi: 10.1016/j.eprac.2026.04.006. Online ahead of print.ABSTRACTPatients with cystic fibrosis (pwCF) often have significant baseline endocrine […]
Mode de vie et approches complémentaires
- Pilot and Feasibility Study of an Individualized Telehealth Exercise Program for People with Cystic Fibrosison 11 mai 2026
J Funct Morphol Kinesiol. 2026 Mar 26;11(2):136. doi: 10.3390/jfmk11020136.ABSTRACTBackground: The Cystic Fibrosis Foundation (CFF) recognizes exercise as a critical part of managing cystic fibrosis […]
- Mediating effects of physical activity enjoyment on physical activity levels in adults with cystic fibrosison 11 mai 2026
Front Sports Act Living. 2026 Mar 27;8:1786911. doi: 10.3389/fspor.2026.1786911. eCollection 2026.ABSTRACTBACKGROUND: This study aimed to investigate the mediating effect of physical activity […]
- Melatonin Supplementation Improves Pain, Sleep Quality, and Total Plasma Antioxidant Capacity in Women with Fibrocystic Breast Disease: A Randomized, Double-blind, Placebo-controlled Trialon 11 mai 2026
J Res Pharm Pract. 2026 Feb 24;15(1):6. doi: 10.4103/jrpp.jrpp_63_25. eCollection 2026.ABSTRACTOBJECTIVE: Fibrocystic breast disease (FBD) is a prevalent benign breast disorder primarily affecting […]
Expériences des patients et des institutions
- Determinants of health-related quality of life in adults with cystic fibrosis: the role of selected sociodemographic and treatment-related factorson 11 mai 2026
Orphanet J Rare Dis. 2026 Apr 24. doi: 10.1186/s13023-026-04362-x. Online ahead of print.NO ABSTRACTPMID:42032769 | DOI:10.1186/s13023-026-04362-x
- "An Amazing Transformation!" The Lived Experiences of Elexacaftor/Tezacaftor/Ivacaftor in Adults with Cystic Fibrosis.on 11 mai 2026
Respiration; 04/01/2026Introduction: Cystic fibrosis (CF) is associated with a high respiratory symptom and treatment burden. Elexacaftor/tezacaftor/ivacaftor (ETI) provides substantial improvements […]
- When health changes everything: The disruptive side of identity shifts in people with CF.on 11 mai 2026
Health: An Interdisciplinary Journal for the Social Study of Health, Illness & Medicine; 05/01/2026Cystic fibrosis (CF) is a severe genetic disorder historically associated with low life […]
- A qualitative exploration of the experiences of adults with cystic fibrosis unable to benefit from triple combination therapy.on 11 mai 2026
Journal of Health Psychology; 05/01/2026Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a highly effective modulator therapy that has transformed the lives of many people with Cystic Fibrosis (CF). […]
- Representation of Minoritized People with Cystic Fibrosis in CF Therapeutics Development Network Clinical Trialson 11 mai 2026
Ann Am Thorac Soc. 2026 Apr 11:aaoag085. doi: 10.1093/annalsats/aaoag085. Online ahead of print.ABSTRACTRATIONALE: Black and Hispanic people with CF (PwCF) experience worse health outcomes related to […]
- Adherence to elexacaftor/tezacaftor/ivacaftor (ETI) among people with cystic fibrosis: the yETI studyon 11 mai 2026
Ann Am Thorac Soc. 2026 Apr 11:aaoag100. doi: 10.1093/annalsats/aaoag100. Online ahead of print.NO ABSTRACTPMID:41975078 | DOI:10.1093/annalsats/aaoag100
- When Transplant Is No Longer the Answer: An End-of-Life Social Work Narrative in Pediatric Cystic Fibrosison 11 mai 2026
J Soc Work End Life Palliat Care. 2026 May 3:1-5. doi: 10.1080/15524256.2026.2666511. Online ahead of print.NO ABSTRACTPMID:42070140 | DOI:10.1080/15524256.2026.2666511
- Impact of the COVID-19 pandemic on sex-related disparities in cystic fibrosis healthcare utilization and outcomes: A population studyon 11 mai 2026
PLoS One. 2026 May 6;21(5):e0345009. doi: 10.1371/journal.pone.0345009. eCollection 2026.ABSTRACTBACKGROUND: The COVID-19 pandemic disrupted healthcare utilization and access for many, with persons […]
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
|
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |


